extract: 2025-12-01-who-glp1-global-guidelines-obesity

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -51,7 +51,7 @@ The BALANCE Model directly addresses the chronic use inflation problem by requir
 ### Additional Evidence (extend)
 *Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16*
 
-WHO issued conditional recommendations (not full endorsement) for GLP-1s in obesity treatment, acknowledging 'limited long-term evidence.' The conditional framing and emphasis on cost-effectiveness analysis, budget impact, and ethical implications by country income level suggests uncertainty about whether the chronic use economics will prove sustainable, especially in low/middle-income countries where WHO guidelines have greatest influence.
+WHO issued conditional recommendations (not full endorsements) for GLP-1s, acknowledging 'limited long-term evidence' and requiring countries to consider 'local cost-effectiveness, budget impact, and ethical implications.' The conditional framing and emphasis on budget impact analysis suggests WHO recognizes the chronic use cost challenge, particularly for low/middle-income countries where affordability is a barrier to sustained treatment.
 
 ---
 

domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md

@@ -45,7 +45,7 @@ The NHS paradox—ranking 3rd overall while having catastrophic specialty access
 ### Additional Evidence (confirm)
 *Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16*
 
-WHO's three-pillar framework for GLP-1 implementation explicitly positions medication as one component within a comprehensive approach requiring healthy diets, physical activity, professional support, and population-level policies. The framework treats obesity as a 'societal challenge requiring multisectoral action — not just individual medical treatment,' directly supporting the view that medical interventions alone cannot address health outcomes dominated by behavioral and social factors.
+WHO's three-pillar framework for GLP-1 treatment explicitly positions medication as one component within a comprehensive approach including healthy diets, physical activity, professional support, and population-level policies. WHO states obesity is a 'societal challenge requiring multisectoral action — not just individual medical treatment,' directly supporting the view that medical interventions alone cannot address health outcomes driven by behavioral and social factors.
 
 ---
 

domains/internet-finance/futarchy-governed-memecoin-launchpads-face-reputational-risk-tradeoff-between-adoption-and-credibility.md

@@ -27,6 +27,12 @@ From the MetaDAO proposal:
 
 This claim extends futarchy-governed-permissionless-launches-require-brand-separation-to-manage-reputational-liability-because-failed-projects-on-a-curated-platform-damage-the-platforms-credibility by showing the reputational concern operates at the mechanism level, not just the platform level. The market's rejection of Futardio suggests futarchy stakeholders prioritize mechanism credibility over short-term adoption metrics.
 
+
+### Additional Evidence (confirm)
+*Source: [[2026-03-05-futardio-launch-phonon-studio-ai]] | Added: 2026-03-16*
+
+Phonon Studio AI raised $88,888 target but ended in 'Refunding' status within one day (launched 2026-03-05, closed 2026-03-06). The project had live product traction (1000+ songs generated in first week, functional tokenized AI artist logic) but still failed to attract capital, suggesting futarchy-governed launches face quality perception issues even when projects demonstrate real product-market validation.
+
 ---
 
 Relevant Notes:

domains/internet-finance/metadao-ico-platform-demonstrates-15x-oversubscription-validating-futarchy-governed-capital-formation.md

@@ -56,10 +56,16 @@ Hurupay raised $2,003,593 against a $3,000,000 target (67% of goal) and entered
 
 
 ### Additional Evidence (challenge)
-*Source: [[2026-03-03-futardio-launch-cloak]] | Added: 2026-03-16*
+*Source: 2026-03-03-futardio-launch-cloak | Added: 2026-03-16*
 
 Cloak raised only $1,455 against a $300,000 target (0.5% of target), entering refunding status. This represents a near-total failure of market validation, contrasting sharply with the 15x oversubscription pattern. The project had shipped product (live mainnet beta with Oro integration), had credible team (repeat builders, Superteam contributors), and addressed a real problem (MEV extraction on DCA orders). Despite these fundamentals, the futarchy-governed raise failed to attract capital, suggesting that product-market fit and team credibility are insufficient without pre-existing community or distribution.
 
+
+### Additional Evidence (challenge)
+*Source: [[2026-03-05-futardio-launch-phonon-studio-ai]] | Added: 2026-03-16*
+
+Phonon Studio AI launch failed to reach its $88,888 target and entered refunding status, demonstrating that not all futarchy-governed raises succeed. The project had demonstrable traction (live product, 1000+ songs generated, functional token mechanics) but still failed to attract sufficient capital, suggesting futarchy capital formation success is not uniform across project types or market conditions.
+
 ---
 
 Relevant Notes:

inbox/archive/2025-12-01-who-glp1-global-guidelines-obesity.md

@@ -46,7 +46,7 @@ EXTRACTION HINT: The WHO position supports the BALANCE model's design but questi
 
 
 ## Key Facts
-- WHO issued GLP-1 obesity treatment guidelines on December 1, 2025
-- WHO framework has three pillars: healthier environments through policy, protecting high-risk individuals, lifelong person-centered care
-- WHO recommendations are conditional, acknowledging limited long-term evidence
-- WHO emphasizes countries must consider local cost-effectiveness, budget impact, and ethical implications
+- WHO issued conditional (not full) recommendations for GLP-1 medicines in obesity treatment in December 2025
+- WHO framework has three pillars: population-level policies, high-risk protection, and person-centered care
+- WHO guideline emphasizes GLP-1s must be combined with healthy diets, physical activity, and professional support
+- WHO requires countries to assess local cost-effectiveness and budget impact before adoption

inbox/archive/2026-03-05-futardio-launch-phonon-studio-ai.md

@@ -6,9 +6,13 @@ url: "https://www.futard.io/launch/x1yqPH8mutuiqkrz66DPwFw1ykQqT4v5KyUUtUzBgPA"
 date: 2026-03-05
 domain: internet-finance
 format: data
-status: unprocessed
+status: enrichment
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
+processed_by: rio
+processed_date: 2026-03-16
+enrichments_applied: ["futarchy-governed-memecoin-launchpads-face-reputational-risk-tradeoff-between-adoption-and-credibility.md", "metadao-ico-platform-demonstrates-15x-oversubscription-validating-futarchy-governed-capital-formation.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Launch Details
@@ -173,3 +177,13 @@ Phonon is already live which means there is real product market validation, meas
 - Token mint: `J697wnGGP8yWhYSrrMNsfH7cpKqp8up4uteigCHZmeta`
 - Version: v0.7
 - Closed: 2026-03-06
+
+
+## Key Facts
+- Phonon Studio AI launched on Futardio 2026-03-05 with $88,888 USDC target
+- Phonon Studio AI fundraise entered refunding status by 2026-03-06
+- Phonon generated 1000+ AI songs in first week of operation
+- Phonon uses Meteora Dynamic Bonding Pool protocol for artist token trading
+- Phonon proposed $11,777 monthly operational allowance
+- Phonon token: J69, mint address J697wnGGP8yWhYSrrMNsfH7cpKqp8up4uteigCHZmeta
+- Phonon launch address: x1yqPH8mutuiqkrz66DPwFw1ykQqT4v5KyUUtUzBgPA